Supplemental material
Drug Delivery
Volume 25, 2018 - Issue 1
Related Research Data
Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension
Source:
Ovid Technologies (Wolters Kluwer Health)
Primary Pulmonary Hypertension
Source:
Elsevier BV
Adrenergic receptor genotype influences heart failure severity and β-blocker response in children with dilated cardiomyopathy
Source:
Springer Nature
Selexipag for the treatment of pulmonary arterial hypertension
Source:
Informa UK Limited
Vardenafil in Pulmonary Arterial Hypertension
Source:
American Thoracic Society
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study
Source:
American Thoracic Society
Clinical classification of pulmonary hypertension
Source:
Elsevier BV
Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension
Source:
Springer Nature
Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension
Source:
Elsevier BV
Primary Pulmonary Hypertension
Source:
Elsevier BV
Comparative Effectiveness of Oral Medications for Pulmonary Arterial Hypertension
Source:
International Heart Journal (Japanese Heart Journal)
Selexipag for the treatment of pulmonary arterial hypertension
Source:
Informa UK Limited
Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension
Source:
American College of Physicians
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Source:
Massachusetts Medical Society
Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials
Source:
Dove Medical Press Ltd.
Primary Pulmonary Hypertension
Source:
Elsevier BV
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
Source:
European Respiratory Society (ERS)
Selexipag for the treatment of pulmonary arterial hypertension
Source:
Informa UK Limited
Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial
Source:
Elsevier BV
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Source:
Massachusetts Medical Society
Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Bosentan Therapy in Patients With Eisenmenger Syndrome
Source:
Ovid Technologies (Wolters Kluwer Health)
Primary Pulmonary Hypertension
Source:
Elsevier BV
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Source:
Massachusetts Medical Society
Selexipag for the treatment of pulmonary arterial hypertension
Source:
Informa UK Limited
Bosentan therapy for pulmonary arterial hypertension
Source:
Oxford University Press (OUP)
Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension
Source:
Ovid Technologies (Wolters Kluwer Health)
Wide Variation in Clinicians' Assessment of New York Heart Association/World Health Organization Functional Class in Patients With Pulmonary Arterial Hypertension
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome
Source:
European Respiratory Society (ERS)
Primary Pulmonary Hypertension
Source:
Elsevier BV
Results of a Randomized Trial
Source:
American College of Physicians
Updated Treatment Algorithm of Pulmonary Arterial Hypertension
Source:
Elsevier BV
A Randomized, Controlled Trial
Source:
American College of Physicians
Sensory and Affective Aspects of Dyspnea Contribute Differentially to the Borg Scale’s Measurement of Dyspnea
Source:
S. Karger AG
Wide Variation in Clinicians' Assessment of New York Heart Association/World Health Organization Functional Class in Patients With Pulmonary Arterial Hypertension
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension
Source:
Taylor & Francis
Primary Pulmonary Hypertension
Source:
Elsevier BV
A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension
Source:
Taylor & Francis
A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension
Source:
Taylor & Francis
Survival in Patients with Primary Pulmonary Hypertension
Source:
American College of Physicians
Beraprost therapy for pulmonary arterial hypertension
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension
Source:
Elsevier BV
Primary Pulmonary Hypertension
Source:
Elsevier BV
Pulmonary Hypertension and Right Heart Failure in Patients With β-Thalassemia Intermedia
Source:
Elsevier BV
Long-Term Therapy with Oral Treprostinil in Pulmonary Arterial Hypertension Failed to Lead to Improvement in Important Physiologic Measures: Results from a Single Center
Source:
SAGE Publications
Bosentan therapy for pulmonary arterial hypertension
Source:
Oxford University Press (OUP)
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
Source:
European Respiratory Society (ERS)
Simultaneous aortic, jugular bulb, and right atrial pressures during cardiopulmonary resuscitation in humans. Insights into mechanisms.
Source:
Ovid Technologies (Wolters Kluwer Health)
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
World Health Organization Group I Pulmonary Hypertension
Source:
Elsevier BV
Primary Pulmonary Hypertension
Source:
Elsevier BV
Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review
Source:
European Respiratory Society (ERS)
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Source:
Massachusetts Medical Society
Endothelin Receptor Antagonists
Source:
Kluwer Academic Publishers
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial
Source:
Elsevier BV
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
Source:
European Respiratory Society (ERS)
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: A network meta-analysis
Source:
Elsevier BV
Primary Pulmonary Hypertension
Source:
Elsevier BV
Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Source:
Elsevier BV
Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension
Source:
European Respiratory Society (ERS)
The 6-min walk distance in healthy subjects: reference standards from seven countries
Source:
European Respiratory Society (ERS)
Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial
Source:
Oxford University Press (OUP)
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Source:
Massachusetts Medical Society
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
Source:
Oxford University Press (OUP)
Primary Pulmonary Hypertension
Source:
Elsevier BV
Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan
Source:
Elsevier BV
Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial
Source:
Oxford University Press (OUP)
Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension
Source:
Ovid Technologies (Wolters Kluwer Health)
Primary Pulmonary Hypertension
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Primary Pulmonary Hypertension
Source:
Elsevier BV
PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension
Source:
European Respiratory Society (ERS)
Primary Pulmonary Hypertension
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension
Source:
SAGE Publications
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Sitaxsentan therapy for pulmonary arterial hypertension
Source:
American Thoracic Society
Pulmonary Arterial Hypertension
Source:
Ovid Technologies (Wolters Kluwer Health)
Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension
Source:
Informa UK Limited
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension: A Randomized Controlled Clinical Trial
Source:
Elsevier BV
Tadalafil Therapy for Pulmonary Arterial Hypertension
Source:
HAL CCSD
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Pulmonary Arterial Hypertension : Baseline Characteristics From the REVEAL Registry
Source:
Elsevier BV
Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics
Source:
Future Medicine Ltd
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial
Source:
Elsevier BV
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)
Source:
European Respiratory Society (ERS)
Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension
Source:
American Thoracic Society
Linking provided by
